Considering these pharmacokinetic and pharmacodynamic profiles, fulvestrant’s pure ER blockade and bazedoxifene’s combined ER modulation and anti-inflammatory activity may act synergistically to attenuate VEGF-driven vascular permeability and inflammatory cascades during OHSS. The gene discussed is ESR1; the disease is ovarian hyperstimulation syndrome.